Patents by Inventor Chandra Vargeese
Chandra Vargeese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132894Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: ApplicationFiled: September 29, 2022Publication date: April 25, 2024Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
-
Publication number: 20240117347Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: ApplicationFiled: December 6, 2022Publication date: April 11, 2024Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena, Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
-
Publication number: 20240109931Abstract: Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: ApplicationFiled: October 4, 2022Publication date: April 4, 2024Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Hanna Maria Wisniewska-wrona, Xiayun Cheng, Young Jin Cho
-
Publication number: 20240026358Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: March 11, 2022Publication date: January 25, 2024Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto, Jayakanthan Kumarasamy, Anthony Lamattina, Tom Liantang Pu
-
Publication number: 20230392137Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: September 26, 2022Publication date: December 7, 2023Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto, Jayakanthan Kumarasamy, Anthony Lamattina, Tom Liantang Pu
-
Publication number: 20230348524Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: ApplicationFiled: March 17, 2023Publication date: November 2, 2023Inventors: Keith Andrew Bowman, Chandra Vargeese, David Charles Donnell Butler, Pachamuthu Kandasamy, Mohammed Rowshon Alam, Mamoru Shimizu, Stephany Michelle Standley, Vincent Aduda, Gopal Reddy Bommineni, Snehlata Tripathi, Ilia Korboukh
-
Publication number: 20230329201Abstract: Among other things, the present disclosure provides cells and non-human animals engineered to express an ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, the present disclosure provides cells and non-human animals engineered to express a human ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, non-human animals are genetically modified rodents such as mice, rat, etc. In some embodiments, non-human animals are mice. In some embodiments, the present disclosure provides technologies for assessing an agent comprising administering the agent to a cell or non-human animal engineered to express an ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, such a cell or non-human animal is engineered to express a human ADAR1 polypeptide or a characteristic portion thereof. In some embodiments, an agent is a pharmaceutical agent. In some embodiments, an agent is or comprises an oligonucleotide.Type: ApplicationFiled: August 23, 2021Publication date: October 19, 2023Inventors: Hailin Yang, Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Jack David Godfrey, Naoki Iwanmoto
-
Publication number: 20230295619Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods for preventing and/ or treating various conditions, disorders or diseases. In some embodiments, provided technologies comprise nucleobase modifications, sugar modifications, intemucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, provided technologies target MAPT. In some embodiments, the present disclosure provides MAPT oligonucleotides, compositions and methods for preventing and/or treating MAPT-associated conditions, disorders or diseases, such as Alzheimer’s Disease (AD) or Frontotemporal Dementia (FTD).Type: ApplicationFiled: February 26, 2021Publication date: September 21, 2023Inventors: Abbie Madeline Maguire, Priyanka Shiva Prakasha, Naoki Iwamoto, Kenneth Allan Longo, Chandra Vargeese, Kevin Kim, Elena Dale, Pachamuthu Kandasamy, Mamoru Shimizu
-
Publication number: 20230295617Abstract: In some embodiments, the present disclosure pertains to compositions and methods related to delivery of a biologically active agent, wherein the compositions comprise a biologically active agent and a lipid. In various embodiments, the lipid is selected from: lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, docosahexaenoic acid (cis-DHA), turbinaric acid and dilinoleyl. In some embodiments, a composition and method are useful for delivery of a biologically active agent to a particular cell or tissue, e.g., a muscle cell or tissue.Type: ApplicationFiled: November 30, 2022Publication date: September 21, 2023Inventors: Chandra Vargeese, Jason Jingxin Zhang, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Naoki Iwamoto, Hailin Yang, Maria David Frank-Kamenetsky, Subramanian Marappan
-
Patent number: 11739325Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: GrantFiled: August 7, 2018Date of Patent: August 29, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Jean-Cosme Dodart, Yuanjing Liu, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Patent number: 11718638Abstract: The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.Type: GrantFiled: June 21, 2018Date of Patent: August 8, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Christopher P. Hencken, Naoki Iwamoto, Pachamuthu Kandasamy, Alvaro Andres Lanao, Genliang Lu, Mamoru Shimizu, Sethumadhavan Divakaramenon, Chandra Vargeese, Gopal Reddy Bommineni, Subramanian Marappan
-
Publication number: 20230220384Abstract: Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.Type: ApplicationFiled: October 6, 2020Publication date: July 13, 2023Inventors: Prashant Monian, Chikdu Shakti Shivalila, Subramanian Marappan, Chandra Vargeese, Pachamuthu Kandasamy, Genliang Lu, Hui Yu, David Charles Donnell Butler, Luciano Henrique Apponi, Mamoru Shimizu, Stephany Michelle Standley, David John Boulay, Andrew Guzior Hoss, Jigar Desai, Jack David Godfrey, Hailin Yang, Naoki Iwamoto
-
Publication number: 20230203484Abstract: The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g, modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, and/or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)), and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g, RNA interference (RNAi) activity, stability, delivery, etc. The present disclosure also provides methods for treatment of diseases using provided double stranded oligonucleotide compositions, for example, in RNA interference.Type: ApplicationFiled: May 24, 2021Publication date: June 29, 2023Applicant: WAVE LIFE SCIENCES LTD.Inventors: Chandra VARGEESE, Naoki IWAMOTO, Luciano H. APPONI, David Charles Donnell BUTLER, Pachamuthu KANDASAMY, Subramanian MARAPPAN, Snehlata TRIPATHI, Wei LIU, Mugdha BEDEKAR, Vinod VATHIPADIEKAL
-
Publication number: 20230203087Abstract: The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.Type: ApplicationFiled: May 24, 2021Publication date: June 29, 2023Inventors: Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Chandra Vargeese, Subramanian Marappan, Gopal Reddy Bommineni, Mamoru Shimizu, Naoki Iwamoto, Stephany Michelle Standley, Yuanjing Liu, Amy Jada Andreucci, Genliang Lu, Onanong Chivatakarn, Akbar Husain Khan
-
Publication number: 20230145795Abstract: Among other things, the present disclosure provides RHO oligonucleotides, compositions, and methods. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, the present disclosure provides RHO oligonucleotides, compositions and methods for preventing and/or treating RHO-related conditions, disorders or diseases, such as retinopathy (e.g, retinal degeneration, retinal degenerative disease, retinal degenerative disorder, inherited retinal degenerative disorder, retinitis pigmentosa, autosomal dominant retinitis pigmentosa, etc.).Type: ApplicationFiled: April 24, 2020Publication date: May 11, 2023Inventors: Michael John Byrne, Vinod Vathipadiekal, Naoki Iwamoto, Chandra Vargeese, Lankai Guo, Andrew Guzior Hoss
-
Patent number: 11634710Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: GrantFiled: February 4, 2020Date of Patent: April 25, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Maria David Frank-Kamenetsky, Hailin Yang, Aaron Jay Morris, Chandra Vargeese, Christopher J. Francis
-
Publication number: 20230089442Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: ApplicationFiled: March 19, 2020Publication date: March 23, 2023Inventors: Pachamuthu Kandasamy, Mamoru Shimizu, David Charles Donnell Butler, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Mohammed Rowshon Alam, Sethumadhavan Divakaramenon, Bijay Tilak Bhattarai, Chandra Vargeese, Keith Andrew Bowman, Stephany Michelle Standley
-
Patent number: 11608355Abstract: Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.Type: GrantFiled: September 17, 2018Date of Patent: March 21, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Keith Andrew Bowman, Chandra Vargeese, David Charles Donnell Butler, Pachamuthu Kandasamy, Mohammed Rowshon Alam, Mamoru Shimizu, Stephany Michelle Standley, Vincent Aduda, Gopal Reddy Bommineni, Snehlata Tripathi, Ilia Korboukh
-
Patent number: 11603532Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: GrantFiled: June 1, 2018Date of Patent: March 14, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
-
Patent number: 11597927Abstract: Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or N patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: GrantFiled: June 1, 2018Date of Patent: March 7, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho